Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma, Ductal × exemestane × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 105 Neoplasm Metastasis 9 Ovarian Neoplasms 3 Carcinoma, Intraductal, Noninfiltrating 3 Breast Neoplasms, Male 3 Prostatic Neoplasms 2 Obesity 2 Carcinoma, Non-Small-Cell Lung 2 Breast Diseases 2 Breast Carcinoma In Situ 2 Breast Cancer Metastatic 2 Arthralgia 2 Triple Negative Breast Neoplasms 1 Sexuality 1 Recurrence 1 Primary Breast Cancer ER+ve 1 Premenopausal Breast Cancer 1 Patient Acceptance of Health Care 1 Pancreatic Neoplasms 1 Pain 1 Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1 Multiple Endocrine Neoplasia Type 1 1 Metastatic Beast Cancer 1 Locoregional Recurrence 1 Hyperglycemia 1 Human Epidermal Growth Factor 2 Negative Carcinoma of Breast 1 Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1 Hormone Receptor Positive Malignant Neoplasm of Breast 1 HR Positive HER2 Negative Advanced Breast Cancer 1 HER2-positive Breast Cancer 1

Interventions

talimogene laherparepvec 1 exemestane 1 Therapeutics 1 Telomerase 1 Tamoxifen 1 Surgical Procedures, Operative 1 Specimen Handling 1 Sentinel Lymph Node Biopsy 1 Radiation, Ionizing 1 Paclitaxel 1 Mastectomy, Subcutaneous 1 Mastectomy, Segmental 1 Mammaplasty 1 Letrozole 1 Indocyanine Green 1 Brachytherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07499999 2026-03-30

BabyTEARS

Dana-Farber Cancer Institute

Phase 2 Not yet recruiting

Breast Neoplasms, Carcinoma, Ductal

Data powered by HemOnc (CC BY 4.0) Colophon ⚡